Bank of New York Mellon Corp Boosts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Bank of New York Mellon Corp boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 399,584 shares of the specialty pharmaceutical company's stock after acquiring an additional 27,134 shares during the quarter. Bank of New York Mellon Corp owned about 0.72% of Supernus Pharmaceuticals worth $14,449,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Quartz Partners LLC increased its stake in Supernus Pharmaceuticals by 3.0% during the fourth quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company's stock worth $1,031,000 after acquiring an additional 820 shares during the last quarter. Handelsbanken Fonder AB increased its stake in Supernus Pharmaceuticals by 11.0% during the fourth quarter. Handelsbanken Fonder AB now owns 19,116 shares of the specialty pharmaceutical company's stock worth $691,000 after acquiring an additional 1,900 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at $92,000. Principal Financial Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 4.0% in the fourth quarter. Principal Financial Group Inc. now owns 296,732 shares of the specialty pharmaceutical company's stock valued at $10,730,000 after buying an additional 11,321 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D grew its stake in shares of Supernus Pharmaceuticals by 3.9% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 59,081 shares of the specialty pharmaceutical company's stock valued at $2,136,000 after buying an additional 2,196 shares in the last quarter.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SUPN shares. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday.

Supernus Pharmaceuticals Trading Up 0.3 %

NASDAQ:SUPN traded up $0.09 during midday trading on Friday, reaching $31.26. The company had a trading volume of 526,106 shares, compared to its average volume of 564,157. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of 29.22 and a beta of 0.83. The stock's fifty day simple moving average is $36.22 and its 200-day simple moving average is $35.17. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.